Form 4 for FDMT 4D Molecular Therapeutics, Inc.
Accepted 2023-05-16 00:00:00 ET · period of report 2023-05-15 · accession 0001610717-23-000044 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-05-16 | 2023-05-15 | FDMT | Moretti August J | CFO | M - OptEx | $9.41 | +3,000 | 11.0K | +37% | +$28.2K |
| D | 2023-05-16 | 2023-05-15 | FDMT | Moretti August J | CFO | M - OptEx | $0.00 | -3,000 | 217.1K | -1% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-15 | M | A | 3,000 | $9.41 | 11,045 | D | — | — | (F1) Reflects 1,450 shares of the Issuer's common stock purchased under the Issuer's Employee Stock Purchase Plan in a transaction exempt from Rule 16b-3. |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-05-15 | M | D | 3,000 | $0.00 | 217,060 | D | $9.41 · — to 2029-03-19 | 3,000 Common Stock | (F2) The option is fully vested and exercisable |